2
Clinical Trials associated with Isophane Protamine Recombinant Human Insulin (BIOTON) / CompletedNot Applicable A Prospective Multi-centre, Non-randomized, Open-label, Non-interventional Study to Evaluate the Safety, Efficacy and Injection Compliance of Scilin N, Scilin R or Scilin M30 in Chinese Type 2 Diabetes Mellitus (T2DM)
This is a prospective, multi-center, open-label, non-interventional, 12-week study in people with type 2 diabetes mellitus who are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice. The term study insulins will be used in this protocol for these drugs and combinations.
Organization Program of DiabEtes INsulIN ManaGement: An Open, Multi-center, Prospective, Randomized, 16-week, Controlled Clinical Study
Diabetes is a common, costly condition associated with significant morbidity and mortality. Diabetes self-management education, the process of teaching individuals to manage their diabetes, has been considered an important part. The intensive education has the capacity to deliver effective interventions to a large number of people. The investigators may be able to redirect our efforts to diabetes care and education strategies that will have a positive impact on the optimization of glycemic control and the prevention of long-term complications of diabetes, reducing the subsequent human and health care costs.
100 Clinical Results associated with Isophane Protamine Recombinant Human Insulin (BIOTON)
100 Translational Medicine associated with Isophane Protamine Recombinant Human Insulin (BIOTON)
100 Patents (Medical) associated with Isophane Protamine Recombinant Human Insulin (BIOTON)
100 Deals associated with Isophane Protamine Recombinant Human Insulin (BIOTON)